Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Marie‑Theresa Weickert"'
Autor:
Maik Herbig, Angela Jacobi, Manja Wobus, Heike Weidner, Anna Mies, Martin Kräter, Oliver Otto, Christian Thiede, Marie‑Theresa Weickert, Katharina S. Götze, Martina Rauner, Lorenz C. Hofbauer, Martin Bornhäuser, Jochen Guck, Marius Ader, Uwe Platzbecker, Ekaterina Balaian
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-8 (2022)
Abstract Diagnosis of myelodysplastic syndrome (MDS) mainly relies on a manual assessment of the peripheral blood and bone marrow cell morphology. The WHO guidelines suggest a visual screening of 200 to 500 cells which inevitably turns the assessor b
Externí odkaz:
https://doaj.org/article/47750a67f89b4072ae8b903f4aa9907e
Autor:
Marie-Theresa Weickert, Judith S. Hecker, Michèle C. Buck, Christina Schreck, Jennifer Rivière, Matthias Schiemann, Katharina Schallmoser, Florian Bassermann, Dirk Strunk, Robert A. J. Oostendorp, Katharina S. Götze
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Abstract Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are clonal hematopoietic stem cell disorders with a poor prognosis, especially for elderly patients. Increasing evidence suggests that alterations in the non-hematopoietic micr
Externí odkaz:
https://doaj.org/article/c226cd0ba70e465cbd553e5471ceb2e7
Autor:
Sebastian Bultmann, Irmela Jeremias, Sylvia Herold, Konstanze Döhner, Verena I. Gaidzik, Sonja Grath, Martina Rudelius, Robert A.J. Oostendorp, Saskia Wolf, Christian Thiede, Stefan Habringer, Anne-Kathrin Garz, Christoph Ziegenhain, Martha Smets, Ulrich Keller, Binje Vick, Marie-Theresa Weickert, Katharina Götze, Christian Peschel
Publikováno v:
Oncotarget
Oncotarget 8, 108738-108759 (2017)
Oncotarget 8, 108738-108759 (2017)
Effectively targeting leukemia-initiating cells (LIC) in FLT3-ITD-mutated acute myeloid leukemia (AML) is crucial for cure. Tyrosine kinase inhibitors (TKI) have limited impact as single agents, failing to eradicate LIC in the bone marrow. Using prim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fce7dd889c37633c59bdea52448db5f
https://mediatum.ub.tum.de/1440363
https://mediatum.ub.tum.de/1440363
Autor:
Saskia Wolf, Robert A.J. Oostendorp, Ulrich Keller, Binje Vick, Anne-Kathrin Garz, Katharina Götze, Marie-Theresa Weickert, Christian Peschel, Karsten Spiekermann, Irmela Jeremias, Stefan Habringer
Publikováno v:
Blood. 126:676-676
Background: Effectively targeting the oncogenic mutation FLT3-ITD remains a crucial goal in acute myeloid leukemia (AML) therapy. Thus far, tyrosine kinase inhibitors (TKI) have not been able to eradicate the earliest leukemia-initiating cells (LIC)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a9d27b4640d1ea22a00a7fbbc2a9e16
https://doi.org/10.1182/blood.v126.23.676.676
https://doi.org/10.1182/blood.v126.23.676.676